Unyango olutsha lwaseTshayina olungelulo oluncinci lomhlaza wemiphunga

# ETshayina Unyango olutsha olungelulo oluNcinane loMhlaza weSeli yeMiphunga yeSeli emincinci Unyango olutsha lomhlaza wemiphunga weseli olungelulo omncinci (NSCLC) luhlala luvela eTshayina. Eli nqaku linika inkcazo yenkqubela phambili yamva nje, igxininise kunyango olujoliswe kuyo, i-immunotherapies, kunye nezinye iindlela ezintsha ezifumanekayo kwizigulane. Siza kuphonononga ubume belizwe Unyango olutsha lwaseTshayina olungelulo oluncinci lomhlaza wemiphunga, egxininisa imiba ephambili yezigulane kunye nabo bazinyamekelayo.

Unyango ekujoliswe kulo lwe-NSCLC e-China

Unyango ekujoliswe kulo lubonisa inkqubela phambili ebalulekileyo Unyango olutsha lwaseTshayina olungelulo oluncinci lomhlaza wemiphunga. La machiza ajolise ngokukodwa kwiinguqu zemfuza eziqhuba ukukhula kweeseli zomhlaza. Iindlela ezininzi zonyango ezijoliswe kuzo zibonise ukuphumelela okuphawulekayo ekwandiseni ubomi kunye nokuphucula umgangatho wobomi kwizigulane ezineenguqu ezithile.

I-EGFR Inhibitors

Iinguqu ze-Epidermal growth factor receptor (EGFR) zixhaphakile kwi-NSCLC, ngakumbi kwizigulane ezingazange zitshaye. Uninzi lwe-EGFR tyrosine kinase inhibitors (TKIs), ezifana ne-gefitinib, i-erlotinib, i-afatinib, i-osimertinib, kunye nezinye, zikhoyo e-China kwaye zibonise ukuphumelela okubonakalayo ekuphatheni i-EGFR-mutated NSCLC. La machiza asebenza ngokuthintela indlela yokubonisa i-EGFR, ukuthintela ukukhula kwethumba. Ukukhethwa kwe-EGFR-TKI ethile kuxhomekeke kwizinto ezifana nohlobo lokuguqulwa kwe-EGFR kunye nempilo yonke yesigulane. Ukusebenza kunye neziphumo ebezingalindelekanga ziyahluka phakathi kwala mayeza.

I-ALK Inhibitors

Ukulungiswa kwakhona kwe-Anaplastic lymphoma kinase (ALK) yenye into engaqhelekanga yofuzo kwi-NSCLC. I-ALK inhibitors, njenge-crizotinib, i-ceritinib, i-alectinib, kunye ne-brigatinib, ijolise ngokufanelekileyo olu tshintsho. Njenge-EGFR TKIs, ukukhethwa kwe-ALK inhibitor efanelekileyo iqwalasela izinto ezifana nokuhlelwa ngokutsha kwe-ALK ethile kunye neempawu zesigulane.

Olunye Unyango Ekujoliswe kulo

Ngaphandle kwe-EGFR kunye ne-ALK inhibitors, ezinye iindlela zonyango ezijoliswe kuzo zifumaneka e-China kwizigulane ze-NSCLC ezineenguqu ezithile zofuzo. Ezi ziquka unyango olujolise kwiinguqu kwi-ROS1, RET, kunye ne-BRAF, phakathi kwabanye. Ubukho kunye nokufikeleleka kolu nyango kunokwahluka ngokwengingqi ngaphakathi eTshayina. Ukuhlala unolwazi ngokubonisana nee-oncologists kubalulekile ekufikeleleni kolu khetho luphambili.

Immunotherapy ye-NSCLC eTshayina

I-Immunotherapy isebenzisa amandla amajoni omzimba okulwa nomhlaza. Le ndlela ibonisa utshintsho lweparadigm Unyango olutsha lwaseTshayina olungelulo oluncinci lomhlaza wemiphunga kwaye ibonise impumelelo ephawulekayo ekuphuculeni iziphumo zokusinda kwizigulane ezininzi.

Izithinteli ze-Immune Checkpoint

I-Immune checkpoint inhibitors (ICIs) yiklasi yeziyobisi ze-immunotherapy ezithintela iiprotheni ezinceda iiseli zomhlaza ukuba ziphephe amajoni omzimba. Iinjongo ezimbini eziphambili kwii-ICIs zicwangcisiwe ukufa-1 (PD-1) kunye neprogram ye-death-ligand 1 (PD-L1). I-Pembrolizumab, i-nivolumab, kunye ne-sintilimab yimizekelo ye-PD-1/PD-L1 inhibitors evunyiweyo e-China ye-NSCLC. Ukusetyenziswa kwe-ICI kudla ngokukhokelwa ngamanqanaba okubonakaliswa kwePD-L1 kwi-tumor, nangona ukusebenza kwabo kudlulela ngaphaya kwe-PD-L1 isimo kwezinye iimeko. Ukubeka iliso ngononophelo kwiziphumo ebezingalindelekanga ezinokubakhona kubalulekile.

Olunye unyango olutsha

Uphando oluqhubekayo luqhubela phambili ukusungula izinto ezintsha kunyango lwe-NSCLC. Iindlela zonyango ezinoveli, kubandakanywa unyango olujoliswe kuyo ngokuchasene ne-biomarkers ekhulayo, indibaniselwano ye-immunotherapy kunye nonyango olujoliswe kuyo, kunye nezinye iindlela ezintsha, ziphantsi kophando kwaye ziqala ukwenza impembelelo ekusebenzeni kweklinikhi. Intsimi ikhula ngokukhawuleza, kwaye ukubonisana rhoqo kunye nababoneleli bezempilo abakhethekileyo kubalulekile ukuba uhlale uhlaziywa kwiinkqubela zamva nje. Ngolwazi oluchanekileyo noluhlaziyiweyo, nceda udibane nogqirha wakho.

Ukukhetha Unyango Olululo

Eyona ndlela yonyango ye-NSCLC e-China yenzelwe umntu kakhulu kwaye ixhomekeke kwizinto ezininzi ezibandakanya inqanaba lomhlaza, utshintsho lwemfuzo olukhoyo, impilo yesigulana iyonke, kunye nokufumaneka konyango oluthile. Iingxoxo kunye ne-oncologist egxile kumhlaza wemiphunga zibalulekile ekumiseleni esona sicwangciso sifanelekileyo sonyango. Iziko loPhando ngoMhlaza laseShandong Baofa (https://www.baofahospital.com/) liziko eliphambili eTshayina elibonelela ngokhathalelo oluphezulu lomhlaza.

Iimpembelelo eziPhakamileyo zoNyango kunye noLawulo

Uninzi lwezonyango zomhlaza, kubandakanywa nezo ze-NSCLC, zinokuba neziphumo ebezingalindelekanga. Ezi ziphumo zecala ziyahluka ngokuxhomekeke kunyango oluthile kunye nesigulane ngasinye. Unxibelelwano oluvulekileyo neqela lakho lezempilo malunga nazo naziphi na iziphumo ebezingalindelekanga zibalulekile ekulawuleni ngempumelelo. Iinkonzo zenkxaso kunye nezicwangciso zokulawula iziphumo ebezingalindelekanga ziyafumaneka ukuqinisekisa intuthuzelo kunye nomgangatho wobomi kulo lonke unyango.

Ukuqukumbela

Imbonakalo yomhlaba ye Unyango olutsha lwaseTshayina olungelulo oluncinci lomhlaza wemiphunga unamandla kwaye uyathembisa. Ukuqhubela phambili kunyango olujoliswe kuyo, unyango lwe-immunotherapy, kunye nezinye iindlela zinika ithemba kwizigulana. Ukufunyaniswa kwangethuba kunye noxilongo olukhawulezileyo kubalulekile ekufikeleleni olona khetho lufanelekileyo nolusebenzayo lonyango. Ukusebenza ngokusondeleyo neqela lakho lokhathalelo lwempilo kubalulekile ukukhangela ubunzima bonyango lwe-NSCLC kwaye ukwandise amathuba akho eziphumo eziyimpumelelo. Khumbula ukudibana ne-oncologist yakho ukuxoxa ngenkqubela phambili yamva nje kunye nesicwangciso sonyango esilungileyo kwimeko yakho ethile.